Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for individual consumer use. The development work was performed in the NanoLogix Laboratory in Hubbard, Ohio. More information on the technology will be released in the near future.
————————————-
James Rogers, PhD, has more than 20 years of biomedical research experience within U.S. Government, contract research organization, and biotechnology industries. This experience includes serving as a Study Director, Principal Investigator, Subject Matter Expert (SME), and Operations Manager executing studies supporting research and development, testing and evaluation, preclinical, and clinical support studies.
From his more than 15 years working at Battelle, Dr. Rogers brings vast experience specializing in the testing and evaluation of medical countermeasures for biological and chemical threat agents. This experience includes transcriptomics/bioinformatics, microRNA analysis, and immunological techniques to investigate biochemical pathways underlying host responses as well as the identification of biomarkers and potential therapeutic targets. He led the development and qualification/validation of several molecular and immune assays to support immunogenicity evaluation, biodistribution studies of vaccines, and clinical trials. He also served as the SME and Program Director for projects that included persistence and decontamination of biological/chemical agents, diagnostic kit and detector testing, and immunotoxicology.
Dr. Rogers received his PhD in Biomedical Sciences from Wright State University, focusing on skin immunology and DNA vaccines. He worked as a post-doc for Geo-Centers, Inc. within the U.S. Air Force Research Laboratory at Wright-Patterson Air Force Base. His research focused on molecular mechanisms associated with volatile organic chemical-induced skin irritation using three-dimensional in vitro and in vivo models.
Dr. Rogers is an author on more than 60 scientific publications and book chapters, presented at national scientific meetings, actively serves on multiple scientific journal Editorial Boards, and served as Book Editor of Microarrays: Principles, Applications and Technologies (Nova Science Publishers, 2014).
Dr. Rogers has been significantly involved in our development of the Coronavirus 19 detection technology. He is also the lead author on multiple peer-reviewed published research papers on NanoLogix technologies from his time at Battelle Biomedical Research Center. We at NanoLogix are extremely grateful to have him join our Team and look forward to a very positive future.